Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.61 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.61 |
| ▸ | MPO | P05164 | 2/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA5A | P35218 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15637306 | 0.86 | MTNR1A (0.63) | MTNR1AMTNR1BMPOCA12CA1 | |
| SCHEMBL9542720 | 0.86 | MTNR1A (0.63) | MTNR1AMTNR1BMPOCA12CA1 | |
| SCHEMBL1255872 | 0.84 | NPSR1 (0.56) | KDM4EALDH1A1KMT2AHPGD | |
| SCHEMBL9776122 | 0.83 | MTNR1A (0.49) | MTNR1AMTNR1BMPOCA12CA1 | |
| SCHEMBL9776110 | 0.83 | MTNR1A (0.49) | MTNR1AMTNR1BMPOCA12CA1 | |
| SCHEMBL9776079 | 0.83 | MTNR1A (0.49) | MTNR1AMTNR1BMPOCA12CA1 | |
| SCHEMBL6234780 | 0.83 | HTR1A (0.47) | MTNR1AMTNR1BCA12CA1CA2 | |
| SCHEMBL9776051 | 0.83 | MTNR1A (0.49) | MTNR1AMTNR1BMPOCA12CA1 | |
| SCHEMBL21243265 | 0.82 | MPO (0.70) | MTNR1AMTNR1BMPOCA12CA1 | |
| SCHEMBL14893135 | 0.81 | MTNR1A (0.74) | MTNR1AMTNR1BCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298781-A1 | COMPOUNDS FOR THE INHIBITION OF APOPTOSIS | CONSEJO SUPERIOR DE (ES) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298781-A1 | COMPOUNDS FOR THE INHIBITION OF APOPTOSIS | BAX, BCL2, CASP3 | MTNR1A 3144/4885MTNR1B 3090/4885MPO 1213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.